Market Place
Sourcing Support
Alnylam to Webcast Presentation at Piper Sandler 36th Conference
27 Nov 2024 //
BUSINESSWIRE
Alnylam Announces Nucresiran Phase 1 Data on TTR Knockdown
17 Nov 2024 //
BUSINESSWIRE
Alnylam abandons clinical-stage Type 2 diabetes asset
31 Oct 2024 //
FIERCE BIOTECH
Alnylam to Present TTR Data & Hypertension Program at AHA 2024
30 Oct 2024 //
BUSINESSWIRE
Alnylam to Webcast Conference Discussing Q3 2024 Financial Results
17 Oct 2024 //
BUSINESSWIRE
Alnylam Submits Application For Vutrisiran In ATTR Amyloidosis
16 Oct 2024 //
BUSINESSWIRE
Alnylam Submits sNDA to FDA For Vutrisiran In ATTR-CM
09 Oct 2024 //
BUSINESSWIRE
Alnylam drops patent lawsuit against Moderna over Covid-19 vaccine
07 Oct 2024 //
ENDPTS
Alnylam: New Data From HELIOS-B Study At Heart Failure Meeting
29 Sep 2024 //
BUSINESSWIRE
Alnylam to Webcast TTR Investor Day
26 Sep 2024 //
BUSINESSWIRE
Alnylam shares slide after heart drug data fails to impress investors
30 Aug 2024 //
REUTERS
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Alnylam To Present HELIOS-B Phase 3 Results At ESC Congress 2024
07 Aug 2024 //
BUSINESSWIRE
Alnylam Reports Q2 2024 Results And Recent Highlights
01 Aug 2024 //
BUSINESSWIRE
Alnylam To Webcast Q2 2024 Financial Results Conference Call
18 Jul 2024 //
BUSINESSWIRE
Alnylam touts `big-win scenario` for closely watched heart trial
25 Jun 2024 //
FIERCE PHARMA
Alnylam Issues 2023 Corporate Responsibility Report
07 May 2024 //
BUSINESSWIRE
Alnylam Reports Q1 2024 Results, Highlights Recent Activity
02 May 2024 //
BUSINESSWIRE
Medison, Alnylam Expand RNAi Deal To More Regions
30 Apr 2024 //
PR NEWSWIRE
Medison, Alnylam Expand RNAi Partnership To More Regions
30 Apr 2024 //
PR NEWSWIRE
Experts paint tough path ahead of Alnylam`s key ATTR-CM readout
22 Apr 2024 //
FIERCE PHARMA
Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
20 Apr 2024 //
PHARMABIZ
Alnylam To Webcast Q1 2024 Financial Results Call
18 Apr 2024 //
BUSINESSWIRE
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
07 Apr 2024 //
BUSINESSWIRE
Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
20 Mar 2024 //
BUSINESSWIRE
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign
13 Mar 2024 //
BUSINESSWIRE
Alnylam takes a family road trip to talk about health history
13 Mar 2024 //
ENDPTS
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
06 Mar 2024 //
BIOPHARMA DIVE
Alnylam Reports Positive KARDIA-2 Topline Study Results
05 Mar 2024 //
BUSINESSWIRE
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
27 Feb 2024 //
BUSINESSWIRE
Alnylam CEO defends changes to crucial ATTR trial
22 Feb 2024 //
ENDPTS
Alnylam Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
BUSINESSWIRE
Alnylam`s last-minute Amvuttra trial change raises doubts
15 Feb 2024 //
FIERCE PHARMA
Alnylam to Webcast Conference Call Discussing Fourth Quarter Financial Results
29 Jan 2024 //
PRESS RELEASE
"Pro Research: Wall Street eyes Alnylam`s RNAi therapeutics potential "
21 Jan 2024 //
PRESS RELEASE
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year
09 Jan 2024 //
BUSINESSWIRE
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Revenues
07 Jan 2024 //
BUSINESSWIRE
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Alnylam Highlights Progress with Platform Innovation and Pipeline at R&D Day
13 Dec 2023 //
BUSINESSWIRE
Alnylam to Webcast Virtual R&D Day
06 Dec 2023 //
PRESS RELEASE
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
30 Nov 2023 //
PRESS RELEASE
Alnylam Presents Results from the KARDIA-1 Phase 2 Study of Zilebesiran
13 Nov 2023 //
BUSINESSWIRE
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
07 Nov 2023 //
BUSINESSWIRE
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
03 Nov 2023 //
NASDAQ
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Alnylam Recognized by Magazine as Top Employer for Fifth Consecutive Year
26 Oct 2023 //
BUSINESSWIRE
Alnylam, Biogen build noise in Alzheimer`s with gene silencing
26 Oct 2023 //
FIERCE BIOTECH
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP
25 Oct 2023 //
BUSINESSWIRE
Alnylam Announces Publication of Results from Phase 3 Study of Patisiran
25 Oct 2023 //
BUSINESSWIRE
Alnylam to Webcast Conference Discussing Third Quarter 2023 Financial Results
19 Oct 2023 //
BUSINESSWIRE
Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran
13 Oct 2023 //
SEEKING ALPHA
FDA Blocks Alnylam’s Bid to Expand Onpattro Label
10 Oct 2023 //
BIOSPACE
Alnylam to Present Data for Patisiran in Patients With ATTR Amyloidosis
06 Oct 2023 //
PRESS RELEASE
Alnylam Stock Trading Halted Today
13 Sep 2023 //
BUSINESSWIRE
Alnylam Announces Positive Outcome of Advisory Committee Meeting on Patisiran
13 Sep 2023 //
BUSINESSWIRE
FDA questions efficacy of Alnylam`s patisiran in disabling ATTR-CM
12 Sep 2023 //
ENDPTS
Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran
07 Sep 2023 //
BUSINESSWIRE
Alnylam plans to appeal Covid-19 vaccine patent ruling in case against Moderna
28 Aug 2023 //
ENDPTS
Alnylam to appeal ruling on patents related to Moderna`s COVID vaccines
26 Aug 2023 //
REUTERS
